We greatly appreciate Dr. Birenbaum's interest and comments on our study of prophylactic phototherapy in ABO incompatibility. In fact, measuring total serum bilirubin (TSB) for infants without ABO incompatibility is not routinely performed in our unit. Instead of that, we found a benefit in comparing between two groups of ABO incompatible neonates, the first group includes neonates who had positive direct Coomb's test (DCT) (n ¼ 242) and the second with negative DCT (n ¼ 851). If we accept that infants with negative DCT have no significant hemolysis, such comparative analysis would, perhaps partially, answer the first enquiry of Dr. Birenbaum.
In revising our data, we found that neonates with positive DCT had significantly more reticulocytes with mean of 7.3±4.4 versus 5.5%±3.6% in negative DCT infants (P<0.0001).
TSB in positive DCT infants was significantly higher at 24 h with mean of 122±49 mmol/l compared to 111±37 mmol/l in the negative DCT neonates (P ¼ 0.007). With the early initiation of phototherapy, the difference in TSB between the two groups became insignificant at 48, 72 and 96 h of life. Umbilical cord hematocrit was significantly lower in infants with positive DCT with a mean of 41%±5% compared to 44%±5% in the negative DCT group (P ¼ 0.0001). These previous results confirm that the degree of hemolysis was significantly more prominent in the positive DCT group.
The number of infants who required phototherapy was significantly lower in negative DCT group (18%) compared to 32% in positive DCT group. Finally, according to our study protocol, infants born by cesarean delivery were considered as discharged at 48 h unless they needed rescue phototherapy. 
